A Phase 1-2 Study of [AC-225]RTX-2358 in People With Sarcoma

Full Title

A Seamless Phase 1/2 Open-Label Study To Evaluate The Safety, Determine The Maximum Tolerated Dose of Administered Activity, and Evaluate The Efficacy of the Therapeutic Radiopharmaceutical [AC-225]RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma

Purpose

Researchers want to find the best dose of [AC-225]RTX-2358 to use safely in people with advanced sarcoma. The people in this study have sarcoma that has come back or keeps growing after treatment.

Ac-225]RTX-2358 is a radioligand drug (a drug with a radioactive part attached to it). It is designed to target cancer cells that make FAP, a protein thought to help cancer cells grow and survive. [Ac-225]RTX-2358 aims to destroy cancer cells while limiting damage to healthy tissue. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have sarcoma that came back or keeps growing after treatment.
• Have completed prior therapies at least 2 weeks before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Sandra D’Angelo’s office at 646-888-4159.